Latest Insider Transactions at Ani Pharmaceuticals Inc (ANIP)
This section provides a real-time view of insider transactions for Ani Pharmaceuticals Inc (ANIP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ANI PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ANI PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 12
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,750
$67.79 P/Share
|
|
Apr 10
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,534
-2.64%
|
$299,244
$66.96 P/Share
|
|
Apr 10
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,799
-2.36%
|
$184,734
$66.96 P/Share
|
|
Apr 01
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-7.32%
|
$1,340,000
$67.25 P/Share
|
|
Mar 23
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,210
-3.49%
|
$428,490
$69.58 P/Share
|
|
Mar 23
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,455
-4.24%
|
$1,204,395
$69.58 P/Share
|
|
Mar 23
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
3,653
-2.98%
|
$252,057
$69.58 P/Share
|
|
Mar 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,500
$66.54 P/Share
|
|
Mar 11
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-6.82%
|
$1,300,000
$65.81 P/Share
|
|
Mar 11
2024
|
Stephen P. Carey SVP & CFO |
SELL
Open market or private sale
|
Direct |
7,787
-4.2%
|
$506,155
$65.55 P/Share
|
|
Mar 08
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,000
-1.19%
|
$670,000
$67.17 P/Share
|
|
Mar 08
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
16,292
-3.81%
|
$1,091,564
$67.13 P/Share
|
|
Mar 07
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,216
-2.22%
|
$278,256
$66.71 P/Share
|
|
Mar 07
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,060
-3.83%
|
$1,125,960
$66.71 P/Share
|
|
Mar 07
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,034
-1.63%
|
$134,244
$66.71 P/Share
|
|
Mar 07
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Open market or private sale
|
Direct |
24,338
-16.35%
|
$1,606,308
$66.37 P/Share
|
|
Mar 07
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,494
-3.02%
|
$164,604
$66.71 P/Share
|
|
Mar 07
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
2,110
-2.41%
|
$139,260
$66.71 P/Share
|
|
Mar 07
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
15,085
-1.76%
|
$995,610
$66.35 P/Share
|
|
Mar 06
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
28,965
-6.11%
|
$1,882,725
$65.52 P/Share
|
|
Mar 06
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
14,822
-1.7%
|
$963,430
$65.47 P/Share
|
|
Mar 05
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,093
-1.14%
|
$656,045
$65.35 P/Share
|
|
Mar 05
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
5,000
-5.41%
|
$330,000
$66.0 P/Share
|
|
Mar 04
2024
|
Antonio R Pera Director |
SELL
Open market or private sale
|
Direct |
7,000
-20.82%
|
$455,000
$65.2 P/Share
|
|
Feb 29
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,122
-1.61%
|
$75,174
$67.67 P/Share
|
|
Feb 29
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,275
-1.36%
|
$85,425
$67.67 P/Share
|
|
Feb 29
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,014
-2.07%
|
$670,938
$67.67 P/Share
|
|
Feb 29
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
1,058
-0.71%
|
$70,886
$67.67 P/Share
|
|
Feb 29
2024
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,173
-2.23%
|
$78,591
$67.67 P/Share
|
|
Feb 29
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Payment of exercise price or tax liability
|
Direct |
1,635
-3.19%
|
$109,545
$67.67 P/Share
|
|
Feb 29
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,570
-1.86%
|
$105,190
$67.67 P/Share
|
|
Feb 29
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,914
-1.0%
|
$128,238
$67.67 P/Share
|
|
Feb 29
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,173
-1.91%
|
$78,591
$67.67 P/Share
|
|
Feb 15
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,244
-1.45%
|
$70,908
$57.55 P/Share
|
|
Feb 15
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,261
-1.33%
|
$71,877
$57.55 P/Share
|
|
Feb 14
2024
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
134,216
+12.88%
|
-
|
|
Feb 14
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
31,316
+15.11%
|
-
|
|
Feb 14
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
22,367
+14.72%
|
-
|
|
Feb 14
2024
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
16,776
+5.43%
|
-
|
|
Feb 14
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Direct |
22,367
+19.45%
|
-
|
|
Feb 14
2024
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
24,605
+13.32%
|
-
|
|
Feb 14
2024
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,131
+17.27%
|
-
|
|
Feb 14
2024
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,790
+8.88%
|
-
|
|
Feb 14
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
24,605
+18.04%
|
-
|
|
Feb 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.67%
|
$14,000
$56.04 P/Share
|
|
Jan 23
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
15,000
-1.67%
|
$840,000
$56.44 P/Share
|
|
Jan 22
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
5,692
-0.63%
|
$313,060
$55.95 P/Share
|
|
Jan 19
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
4,524
-0.5%
|
$248,820
$55.57 P/Share
|
|
Jan 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
9,784
-1.07%
|
$538,120
$55.3 P/Share
|
|
Jan 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,000
-1.08%
|
$550,000
$55.11 P/Share
|